269 related articles for article (PubMed ID: 25294913)
1. A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma.
Sborov DW; Nuovo GJ; Stiff A; Mace T; Lesinski GB; Benson DM; Efebera YA; Rosko AE; Pichiorri F; Grever MR; Hofmeister CC
Clin Cancer Res; 2014 Dec; 20(23):5946-55. PubMed ID: 25294913
[TBL] [Abstract][Full Text] [Related]
2. Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus.
Kelly KR; Espitia CM; Zhao W; Wendlandt E; Tricot G; Zhan F; Carew JS; Nawrocki ST
Oncotarget; 2015 Dec; 6(38):41275-89. PubMed ID: 26513296
[TBL] [Abstract][Full Text] [Related]
3. Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma.
Stiff A; Caserta E; Sborov DW; Nuovo GJ; Mo X; Schlotter SY; Canella A; Smith E; Badway J; Old M; Jaime-Ramirez AC; Yan P; Benson DM; Byrd JC; Baiocchi R; Kaur B; Hofmeister CC; Pichiorri F
Mol Cancer Ther; 2016 May; 15(5):830-41. PubMed ID: 26809490
[TBL] [Abstract][Full Text] [Related]
4. A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: a Children's Oncology Group Phase I Consortium report.
Kolb EA; Sampson V; Stabley D; Walter A; Sol-Church K; Cripe T; Hingorani P; Ahern CH; Weigel BJ; Zwiebel J; Blaney SM
Pediatr Blood Cancer; 2015 May; 62(5):751-8. PubMed ID: 25728527
[TBL] [Abstract][Full Text] [Related]
5. Importin-β and exportin-5 are strong biomarkers of productive reoviral infection of cancer cells.
Nuovo G; Tran H; Gutierrez A; Fadda P; Pichiorri F; Caserta E; Hofmeister CC; Chesi M; Leif Bergsagel P; Morris D; Shi Q; Coffey M; Thirukkumaran C
Ann Diagn Pathol; 2018 Feb; 32():28-34. PubMed ID: 29414394
[TBL] [Abstract][Full Text] [Related]
6. REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors.
Morris DG; Feng X; DiFrancesco LM; Fonseca K; Forsyth PA; Paterson AH; Coffey MC; Thompson B
Invest New Drugs; 2013 Jun; 31(3):696-706. PubMed ID: 22886613
[TBL] [Abstract][Full Text] [Related]
7. Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway.
Twigger K; Roulstone V; Kyula J; Karapanagiotou EM; Syrigos KN; Morgan R; White C; Bhide S; Nuovo G; Coffey M; Thompson B; Jebar A; Errington F; Melcher AA; Vile RG; Pandha HS; Harrington KJ
BMC Cancer; 2012 Aug; 12():368. PubMed ID: 22920673
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma.
Dispenzieri A; Tong C; LaPlant B; Lacy MQ; Laumann K; Dingli D; Zhou Y; Federspiel MJ; Gertz MA; Hayman S; Buadi F; O'Connor M; Lowe VJ; Peng KW; Russell SJ
Leukemia; 2017 Dec; 31(12):2791-2798. PubMed ID: 28439108
[TBL] [Abstract][Full Text] [Related]
9. Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche.
Müller LME; Migneco G; Scott GB; Down J; King S; Askar B; Jennings V; Oyajobi B; Scott K; West E; Ralph C; Samson A; Ilett EJ; Muthana M; Coffey M; Melcher A; Parrish C; Cook G; Lawson M; Errington-Mais F
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741729
[TBL] [Abstract][Full Text] [Related]
10. A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer.
Vidal L; Pandha HS; Yap TA; White CL; Twigger K; Vile RG; Melcher A; Coffey M; Harrington KJ; DeBono JS
Clin Cancer Res; 2008 Nov; 14(21):7127-37. PubMed ID: 18981012
[TBL] [Abstract][Full Text] [Related]
11. Reovirus as a viable therapeutic option for the treatment of multiple myeloma.
Thirukkumaran CM; Shi ZQ; Luider J; Kopciuk K; Gao H; Bahlis N; Neri P; Pho M; Stewart D; Mansoor A; Morris DG
Clin Cancer Res; 2012 Sep; 18(18):4962-72. PubMed ID: 22761466
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma.
Galanis E; Markovic SN; Suman VJ; Nuovo GJ; Vile RG; Kottke TJ; Nevala WK; Thompson MA; Lewis JE; Rumilla KM; Roulstone V; Harrington K; Linette GP; Maples WJ; Coffey M; Zwiebel J; Kendra K
Mol Ther; 2012 Oct; 20(10):1998-2003. PubMed ID: 22871663
[TBL] [Abstract][Full Text] [Related]
13. Reolysin is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer.
Carew JS; Espitia CM; Zhao W; Kelly KR; Coffey M; Freeman JW; Nawrocki ST
Cell Death Dis; 2013 Jul; 4(7):e728. PubMed ID: 23868061
[TBL] [Abstract][Full Text] [Related]
14. Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction, and augments bortezomib-mediated apoptosis in multiple myeloma.
Kelly KR; Espitia CM; Mahalingam D; Oyajobi BO; Coffey M; Giles FJ; Carew JS; Nawrocki ST
Oncogene; 2012 Jun; 31(25):3023-38. PubMed ID: 22002308
[TBL] [Abstract][Full Text] [Related]
15. Modulation of Reoviral Cytolysis (I): Combination Therapeutics.
Mori Y; Nishikawa SG; Fratiloiu AR; Tsutsui M; Kataoka H; Joh T; Johnston RN
Viruses; 2023 Jun; 15(7):. PubMed ID: 37515160
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial.
Nawrocki ST; Olea J; Villa Celi C; Dadrastoussi H; Wu K; Tsao-Wei D; Colombo A; Coffey M; Fernandez Hernandez E; Chen X; Nuovo GJ; Carew JS; Mohrbacher AF; Fields P; Kuhn P; Siddiqi I; Merchant A; Kelly KR
Clin Cancer Res; 2023 Dec; 29(24):5087-5103. PubMed ID: 37812476
[TBL] [Abstract][Full Text] [Related]
17. The combination of intravenous Reolysin and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancer.
Mahalingam D; Patel S; Nuovo G; Gill G; Selvaggi G; Coffey M; Nawrocki ST
BMC Cancer; 2015 Jul; 15():513. PubMed ID: 26156229
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors.
Villalona-Calero MA; Lam E; Otterson GA; Zhao W; Timmons M; Subramaniam D; Hade EM; Gill GM; Coffey M; Selvaggi G; Bertino E; Chao B; Knopp MV
Cancer; 2016 Mar; 122(6):875-83. PubMed ID: 26709987
[TBL] [Abstract][Full Text] [Related]
19. Bovine pestivirus is a new alternative virus for multiple myeloma oncolytic virotherapy.
Marchica V; Franceschi V; Vescovini R; Storti P; Vicario E; Toscani D; Zorzoli A; Airoldi I; Dalla Palma B; Campanini N; Martella E; Mancini C; Costa F; Donofrio G; Giuliani N
J Hematol Oncol; 2020 Jul; 13(1):89. PubMed ID: 32653014
[TBL] [Abstract][Full Text] [Related]
20. Modulation of Reoviral Cytolysis (II): Cellular Stemness.
Bourhill T; Rohani L; Kumar M; Bose P; Rancourt D; Johnston RN
Viruses; 2023 Jun; 15(7):. PubMed ID: 37515162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
